The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

Cell & Gene Therapy Insights 2022; 8(7), 681–685

DOI: 10.18609/cgti.2022.101

Published: 22 July 2022
Dr Wei Li, Dr Daniel Teper

“...the combination of gene editing and iNK platforms offers a powerful platform to unleash the great potential of immuno-oncology cell therapies.”